These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 9747912

  • 61. [A randomized double-blind therapeutic trial of enalapril versus timed-release nifedipine in mild to moderate essential hypertension].
    Artigou JY, Benichou M, Berland J, Fressinaud P, Grollier G, Guéret P, Nguyen Cong Duc L.
    Presse Med; ; 19(1):13-6. PubMed ID: 2137218
    [Abstract] [Full Text] [Related]

  • 62. Effort blood pressure control in the course of antihypertensive treatment.
    de Divitiis O, Di Somma S, Liguori V, Petitto M, Magnotta C, Ausiello M, Natale N, Brignoli M, Galderisi M.
    Am J Med; 1989 Sep 18; 87(3C):46S-56S. PubMed ID: 2782327
    [Abstract] [Full Text] [Related]

  • 63. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
    Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J, Tsalamandris C, Melbourne Diabetic Nephropathy Study Group.
    Diabet Med; 2004 Nov 18; 21(11):1192-9. PubMed ID: 15498085
    [Abstract] [Full Text] [Related]

  • 64. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
    Höglund C, Cifkova R, Mimran A, Tenczer J, Watt A, Wilkins MR, Lindberg E.
    Cardiology; 1998 May 18; 89(4):263-70. PubMed ID: 9643273
    [Abstract] [Full Text] [Related]

  • 65. [Pharmaco-epidemiologic evaluation of rilmenidine in 18,235 hypertensive patients].
    Luccioni R.
    Presse Med; 1995 Dec 09; 24(38):1857-64. PubMed ID: 8545441
    [Abstract] [Full Text] [Related]

  • 66. Left Ventricular Hypertrophy in Hypertensive Athletes can be Reduced by Antihypertensive Medication Despite Continuing Intense Aerobic Exercise.
    Ketelhut S, Franz IW, Ketelhut RG.
    High Blood Press Cardiovasc Prev; 2018 Dec 09; 25(4):385-390. PubMed ID: 30341642
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy.
    Tarnow L, Sato A, Ali S, Rossing P, Nielsen FS, Parving HH.
    Diabetes Care; 1999 Mar 09; 22(3):491-4. PubMed ID: 10097934
    [Abstract] [Full Text] [Related]

  • 70. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
    Mazza A, Montemurro D, Zuin M, Schiavon L, Zorzan S, Chondrogiannis S, Ferretti A, Ramazzina E, Rubello D.
    Minerva Cardioangiol; 2013 Aug 09; 61(4):461-9. PubMed ID: 23846012
    [Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72. Lisinopril versus slow release nifedipine in patients with essential hypertension: a multicentre study.
    Predel HG, Kramer HJ.
    J Hum Hypertens; 1994 Oct 09; 8(10):777-80. PubMed ID: 7837215
    [Abstract] [Full Text] [Related]

  • 73. A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness.
    Suzuki H, Nakamoto H, Okada H, Sugahara S, Kanno Y.
    Adv Perit Dial; 2003 Oct 09; 19():59-66. PubMed ID: 14763035
    [Abstract] [Full Text] [Related]

  • 74. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD.
    Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J.
    Am J Kidney Dis; 2005 Nov 09; 46(5):799-811. PubMed ID: 16253719
    [Abstract] [Full Text] [Related]

  • 75. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial.
    Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E, Schuurman FH, Meyboom-de Jong B, Crijns HJ.
    J Hypertens; 2001 Feb 09; 19(2):303-9. PubMed ID: 11212974
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77. Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients.
    Scognamiglio R, Nosadini R, Marin M, Nisti S, Fasoli G, Palisi M, Frigato F, Virgili F, Carraro A, Crepaldi G.
    Diabetes Care; 1997 Aug 09; 20(8):1290-2. PubMed ID: 9250456
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79. Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging.
    Gaudio C, Tanzilli G, Ferri FM, Villatico Campbell S, Bertocchi F, Motolese M, Campa PP.
    J Cardiovasc Pharmacol; 1998 Nov 09; 32(5):760-8. PubMed ID: 9821850
    [Abstract] [Full Text] [Related]

  • 80. The effects of long-term treatment on left ventricular hypertrophy in patients with essential hypertension: relation to changes in neurohumoral factors.
    Ueno H, Takata M, Tomita S, Oh-hashi S, Yasumoto K, Inoue H.
    J Cardiovasc Pharmacol; 1997 Nov 09; 30(5):643-8. PubMed ID: 9388047
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.